Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$22.4K Buy
+300
New +$21.6K ﹤0.01% 1056
2022
Q1
Sell
-5,550
Closed -$398K 1271
2021
Q4
$398K Buy
+5,550
New +$422K ﹤0.01% 1076
2018
Q4
Sell
-2,976
Closed -$303K 784
2018
Q3
$303K Buy
+2,976
New +$287K ﹤0.01% 686
2017
Q4
Sell
-5,999
Closed -$375K 1062
2017
Q3
$375K Buy
+5,999
New +$355K ﹤0.01% 802
2017
Q2
Sell
-4,643
Closed -$283K 939
2017
Q1
$283K Buy
4,643
+34
+0.7% +$1.92K ﹤0.01% 729
2016
Q4
$253K Buy
+4,609
New +$221K ﹤0.01% 710
2016
Q3
Sell
-15,402
Closed -$524K 561
2016
Q2
$524K Buy
+15,402
New +$481K 0.01% 318

Other funds holding NGVT

Natixis's NGVT Position: Q2 2026 in Review

Natixis opened a new position in Ingevity (NGVT) in Q2 2026: 300 shares worth $22.4K. The stake represents ﹤0.01% of the portfolio and ranks #1056 among its holdings. This is a return to the name: Natixis previously reported a position in NGVT as recently as Q4 2021.

Natixis first reported a position in NGVT in Q2 2016 and has held it in 7 quarters since. The position peaked at $524K in Q2 2016. 316 funds tracked by Wall St. Rank hold NGVT as of Q2 2026.

  • Natixis held 300 shares of Ingevity worth $22.4K as of Q2 2026.
  • Ingevity was a new Natixis position in Q2 2026.
  • Ingevity made up ﹤0.01% of Natixis's portfolio in Q2 2026, its #1056 holding.
  • Natixis first reported a position in Ingevity in Q2 2016 and has held it in 7 quarters since.
  • Natixis's Ingevity position peaked at $524K in Q2 2016.
  • 316 funds tracked by Wall St. Rank held Ingevity as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.